Takeda reported net revenues of $881.4 billion yen ($7.71 billion) in its third quarter fiscal year 2017 results.
Here's what you should know:
1. Takeda increased revenues 3.6 percent year-over-year.
2. Takeda's gastroenterology division was its second strongest, with revenue increasing 24.8 percent year-over-year. Entyvio and Takecab led the growth.
3. Takeda's U.S.-based revenue increased 16.7 percent year-over-year.
4. Takeda's CEO Christophe Weber said in a release, "Our growth drivers continued to deliver robust double-digit revenue growth, which together with our cost management initiatives led to a significant margin expansion. … Although we expect headwinds in the second half of the year, we are still confident to raise our outlook for the full year as we execute against our key mid-term priorities of growing the portfolio, rebuilding the pipeline, and boosting profitability."
5. Concerning end-of-year outlooks, Takeda expects earnings of $1.720 trillion yen ($15.07 billion).